S890 • OFID 2019:6 (Suppl 2) • Poster Abstracts other professionals (32, 13%) and physicians (31, 13%). All posttest questions except one indicated correct responses were selected by ≥80%. In all, 245 provided a course evaluation; 94% agreed the content and materials addressed a gap in their knowledge, and 84% agreed the knowledge gained from the activity could be applied to practice. Nearly all (96%) agreed the delivery methods used was appropriate and aided in learning the content. Suggested improvements included integration of case-based scenarios, Spanish-language materials, and more information on epidemiology and information on TBRDs in vulnerable populations.
Background. Few HIV clinics train HIV providers on initiation of HCV treatment for their coinfected patients. We sought to evaluate the changes in comfort levels, attitude and knowledge of HCV evaluation and treatment among providers over time and track the uptake of treatment initiation.
Methods. Our program was implemented in an urban, Ryan-White outpatient clinic in 2018. Providers were given initial didactics and completed a survey that assessed their level of comfort and knowledge with treating HCV. We developed pocket cards and flow charts to help providers navigate the HCV cascade to cure. Additional training one year later through presentations and case-based discussions was given and the same survey was conducted again. We evaluated the number of HCV evaluation visits in 2018 and prescriptions written for HCV treatment.
Results. The first survey was completed by 21 and the second by 20 out of 28 providers; 70% attended at least one of the trainings. After the initial training, 38% of providers felt "confident" about discussing liver disease progression which increased to 50% after the second training. Similarly, 48% of providers felt "somewhat comfortable" talking about HIV/HCV drug interactions which increased to 80%. 33% of providers noted they were "not comfortable" discussing drug interactions which decreased to 15%. Approximately 1/3 providers felt "confident" talking about HCV treatment in both surveys. About 20% of providers disagreed with treating HIV/HCV patients with active substance use and this did not change. The median knowledge score was 7 (IQR) (6-9) after the first survey and changed to 8(5-9) after the second. Between 2018-2019, 81 HCV evaluation visits were scheduled and 64 (80% Male, 53% Black, 39% uninsured, 23% Medicaid, 73% with history of substance use) were completed and 69% of patients were prescribed HCV treatment. Among all HIV providers, 89% completed a median of 1 (1-3) HCV evaluation visits, and 71% prescribed treatment a median of 1 (1-2).
Conclusion. Implementation of HCV training to all HIV providers requires continued education and resulted in the initiation of HCV evaluation and treatment amongst the large majority of HIV providers who had previously never treated HCV.
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What Predicts Journal Publication Tier and Audience Engagement in the Infectious Diseases Literature? A Review of 146 Publications
Nicolas W. Cortes-Penfield, MD 1 ; Jason Salemi, PhD, MPH 2 ; 1 University of Nebraska Medical Center, Omaha, Texas; 2 Baylor College of Medicine, Houston, Texas Session: 266. Medical Education: Medical School to Practice Saturday, October 5, 2019: 12:15 PM Background. As part of an online medical education project (www.idjournal. club), we surveilled the infectious diseases (ID) literature, selecting subsets of what we deemed the most clinically impactful articles on a monthly basis using a prespecified search algorithm. We used this resource to perform a broad overview of articles published in the field and examine factors associated with publication in higher tier journals and higher rates of public and ID community engagement.
